Skip to content

Investigating the anti-inflammatory effect of colchicine in patients undergoing coronary artery bypass graft

Investigating the anti-inflammatory effect of colchicine in patients undergoing coronary artery bypass graft (CABG) in Semnan kosar hospital in 1401: A randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220907055908N1
Enrollment
90
Registered
2022-09-18
Start date
2022-10-12
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease. Atherosclerotic heart disease of native coronary artery

Interventions

Intervention 1: Intervention group: After conducting an interview and taking history and medical and medical records, 6 cc of blood was taken from the patient and after centrifugation and serum separa

Sponsors

Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients over 30 years old and under 80 years old patients needing CABG surgery Informed consent

Exclusion criteria

Exclusion criteria: patients should have contraindications to colchicine or atorvastatin patients with a history of severe liver diseases patients who have creatinine clearance less than 50. patients with a history of atrial fibrillation or atrial flutter or 2nd and 3rd-degree heart block patients with autoimmune diseases or a history of taking immunosuppressive drugs in the last 1 month patients with heart failure Ejection Fraction < 35% patients with a history of muscle conflicts patients of taking fibrate drugs patients with leukopenia or active infection patients with acute coronary syndrome

Design outcomes

Primary

MeasureTime frame
Interleukin 6. Timepoint: Before and after the intervention. Method of measurement: ELISA method.;CRP. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometry.;LDH. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometry.;ESR. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometry.

Secondary

MeasureTime frame
AF rhythm occurrence. Timepoint: Before and after the intervention. Method of measurement: Electrocardiogram(¬ECG).;Gastrointestinal side effects (nausea, heartache, diarrhea and vomiting). Timepoint: after the intervention. Method of measurement: Examination.;Death. Timepoint: after the intervention. Method of measurement: Examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Zahra Banihashemian

Semnan University of Medical Sciences

seyedehzahra.banihashemian@gmail.com+98 23 3345 1336

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026